ADA Assessment for Cell Therapies

Cell therapies are emerging as promising therapies for a variety of disease indications. The ability to detect anti-drug antibodies (ADA) is important for patients receiving cell-based therapies. However, approaches to detecting ADAs against cell-surface biotherapeutics vary, utilizing either traditional ligand binding assays or cell-based binding assays. This presentation will cover the challenges of both approaches and current industry practices.

Who Should Attend?

  • Bioanalytical scientists
  • Clinical pharmacologists
  • Scientists working on cell therapy programs¬†
Date
-
Address

Virtual

Cost
Free
scroll back to top of page